The negative correlation between the DNMT1 and DNMT3b expression levels and the prognosis of ERα-positive breast cancer patients was consistent with the observations in breast cancer cell lines, suggesting that high expression of DNMT1 and DNMT3b has a detrimental effect on breast cancer drug response. This evidence concerns the gene ESR1 and breast carcinoma.